<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004518.pub2" GROUP_ID="DEPRESSN" ID="468402082012272501" MERGED_FROM="" MODIFIED="2008-11-03 19:33:42 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Exported from Review Manager 4.3&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 18:31:44 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="113" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-11-03 19:33:42 +0100" MODIFIED_BY="Rachel Churchill">
<TITLE>Passiflora for anxiety disorder</TITLE>
<CONTACT MODIFIED="2008-11-03 19:33:42 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="13191" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lincoln Sakiara</FIRST_NAME><LAST_NAME>Miyasaka</LAST_NAME><POSITION>Reviewer</POSITION><EMAIL_1>lincoln.miyasaka@terra.com.br</EMAIL_1><URL>www.centrocochranedobrasil.org</URL><ADDRESS><ORGANISATION>Brazilian Cochrane Centre</ORGANISATION><ADDRESS_1>Universidade Federal de São Paulo</ADDRESS_1><ADDRESS_2>Rua de Pedro Toledo 598, Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-03 19:33:42 +0100" MODIFIED_BY="Rachel Churchill"><PERSON ID="13191" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lincoln Sakiara</FIRST_NAME><LAST_NAME>Miyasaka</LAST_NAME><POSITION>Reviewer</POSITION><EMAIL_1>lincoln.miyasaka@terra.com.br</EMAIL_1><URL>www.centrocochranedobrasil.org</URL><ADDRESS><ORGANISATION>Brazilian Cochrane Centre</ORGANISATION><ADDRESS_1>Universidade Federal de São Paulo</ADDRESS_1><ADDRESS_2>Rua de Pedro Toledo 598, Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON><PERSON ID="5183" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Álvaro</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Atallah</LAST_NAME><SUFFIX>MD, PhD.</SUFFIX><POSITION>Professor of Emergency Medicine and Evidence-Based Medicine, Director of Brazilian Cochrane Centre</POSITION><EMAIL_1>atallahmbe@uol.com.br</EMAIL_1><EMAIL_2>cochrane.dmed@epm.br</EMAIL_2><MOBILE_PHONE>+55 11 8173 0404</MOBILE_PHONE><ADDRESS><DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de  São Paulo / Escola Paulista de Medicina</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598 </ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>CEP 04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><PHONE_2>+55 11 5571 4721</PHONE_2><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON><PERSON ID="9639" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bernardo </FIRST_NAME><LAST_NAME>Soares</LAST_NAME><POSITION>Honorary Fellow</POSITION><EMAIL_1>bgos@terra.com.br</EMAIL_1><ADDRESS><ORGANISATION>Brazilian Cochrane Centre</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1><ADDRESS_2>Vila Clementino</ADDRESS_2><CITY>São Paulo</CITY><ZIP>04039-001</ZIP><REGION>SP</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1><FAX_1>+55 11 5579 0469</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-03 19:33:41 +0100" MODIFIED_BY="Rachel Churchill" NOTES="&lt;p&gt;Minor update: 13/07/06&lt;/p&gt;" NOTES_MODIFIED="2008-11-03 18:31:44 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="13" MONTH="11" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="13" MONTH="11" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="3" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="13" MONTH="11" YEAR="2006"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Brazilian Cochrane Centre</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Passiflora for the treatment of anxiety disorders in adults</TITLE>
<SUMMARY_BODY>
<P>Anxiety is a very common mental health problem in the general population. Passiflora, a herbal medicine, could be an option for treating anxiety if shown to be effective and safe. This review summarised the evidence from currently available studies on passiflora. Only two studies were eligible for inclusion, involving a total of 198 participants. One study showed that passiflora was as effective as benzodiazepines, with similar dropout rates between the two treatments. Given the lack of studies, it is not possible to draw any conclusions on the effectiveness or safety of passiflora in the treatment of anxiety disorders.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Anxiety is a very common mental health problem in the general population and in the primary care setting. Herbal medicines are popularly used worldwide and could be an option for treating anxiety if shown to be effective and safe. Passiflora (passionflower extract) is one of these compounds. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To investigate the effectiveness and safety of passiflora for treating any anxiety disorder. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The following sources were used: electronic databases: Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies), Medline and Lilacs; Cross-checking references; contact with authors of included studies and manufacturers of passiflora.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Relevant randomised and quasi-randomised controlled trials of passiflora using any dose, regime, or method of administration for people with any primary diagnosis of general anxiety disorder, anxiety neurosis, chronic anxiety status or any other mental health disorder in which anxiety is a core symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder). Effectiveness was measured using clinical outcome measures such as Hamilton Anxiety Scale (HAM-A) and other scales for anxiety symptoms.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently selected the trials found through the search strategy, extracted data, performed the trial quality analyses and entered data. Where any disagreements occured, the third reviewer was consulted. Methodological quality of the trials included in this review was assessed using the criteria described in the Cochrane Handbook. For dichotomous outcomes, relative risk with 95% confidence intervals (CI) were calculated, and for continuous outcomes, weighted mean difference with 95%CI was used.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Two studies, with a total of 198 participants, were eligible for inclusion in this review. Based on one study, a lack of difference in the efficacy of benzodiazepines and passiflora was indicated. Dropout rates were similar between the two interventions. Although the findings from one study suggested an improvement in job performance in favour of passiflora (post-hoc outcome) and one study showed a lower rate of drowsiness as a side effect with passiflora as compared with mexazolam, neither of these findings reached statistical significance.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>RCTs examining the effectiveness of passiflora for anxiety are too few in number to permit any conclusions to be drawn. RCTs with larger samples that compare the effectiveness of passiflora with placebo and other types of medication, including antidepressants, are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Anxiety is a very common mental health disturbance in the general population and in the primary care setting. In the US National Comorbidity Survey <LINK REF="REF-Kessler-1994" TYPE="REFERENCE">Kessler 1994</LINK> found a one year prevalence for anxiety disorders of 17% and a lifetime prevalence of almost 25%. Using the Composite International Diagnostic Interview (CIDI) in 1996-99, <LINK REF="REF-Bijl-1998" TYPE="REFERENCE">Bijl 1998</LINK> included 7076 people in 90 municipalities in the Netherlands, and detected a prevalence rate for anxiety of 19.3% in the general population. In Brazil the prevalence of anxiety was reported at 12.1% in Brasilia, 6.9% in São Paulo and 5.4% in Porto Alegre (<LINK REF="REF-Almeida_x002d_Filho-1997" TYPE="REFERENCE">Almeida-Filho 1997</LINK>). One study found a marked reduction in quality of life and psychosocial functioning in people with anxiety disorders (<LINK REF="REF-Mendlowicz-2000" TYPE="REFERENCE">Mendlowicz 2000</LINK>).</P>
<P>Although anxiety is a treatable disease, it is often not diagnosed and treated properly. The majority of patients suffering from anxiety consult their general practitioner, and often their complaint presents as a physical symptom such as headache, palpitations, breathing difficulties or chest pain (<LINK REF="REF-Walley-1994" TYPE="REFERENCE">Walley 1994</LINK>). Anxiety may also be associated with physical disorders, such as diabetes, arthritis and cancer. It may also be the main symptom of a specific psychiatric disorder such as generalized anxiety disorder, postraumatic stress disorder, panic or obsessive compulsive disorder. </P>
<P>Benzodiazepines are effective in short term treatment but their overuse may cause dependence (<LINK REF="REF-Priest-1988" TYPE="REFERENCE">Priest 1988</LINK>). Psychotherapy is effective and commonly used to treat anxiety (<LINK REF="REF-Taylor-1978" TYPE="REFERENCE">Taylor 1978</LINK>, <LINK REF="REF-Taylor-1988" TYPE="REFERENCE">Taylor 1988</LINK>, <LINK REF="REF-Borkovec-1987" TYPE="REFERENCE">Borkovec 1987</LINK>, <LINK REF="REF-Borkovec-1993" TYPE="REFERENCE">Borkovec 1993</LINK>). A systematic review on psychotherapy for generalized anxiety disorder has been conducted and is expected to be published soon in the Cochrane Library (<LINK REF="REF-Hunot--2006" TYPE="REFERENCE">Hunot 2006</LINK>). Another systematic review found that cognitive behavioural therapies and pharmacological treatments including buspirone, trazodone, imipramine and ritanserin significantly improved anxiety (<LINK REF="REF-Gould-1997" TYPE="REFERENCE">Gould 1997</LINK>). However psychotherapy may be an unrealistic option in public health settings in many countries as it is costly and time consuming, and although pharmacological treatments are effective, they may be limited by their side effects and cost. Herbal medicines are popularly used worldwide and could be an option if shown to be effective and safe. A systematic review on the effectiveness of kava kava for anxiety showed its superiority as compared with placebo (<LINK REF="REF-Pittler-2002" TYPE="REFERENCE">Pittler 2002</LINK>). There is no systematic review on passionflower for anxiety.</P>
<P>Passiflora (or Passionflower) is a folk remedy used for anxiety. In Brazil it is called 'maracujá' and its juice is used as a popular beverage. The plant is of the Passifloraceae family with about 400 species is native to North, Central and South America. The beautiful flower that blossoms out of the unassuming bud was compared in the 15th century to the Passion of Christ, and named passionflower by the Spanish explorers who came to Peru (<LINK REF="REF-Olin-1989" TYPE="REFERENCE">Olin 1989</LINK>). </P>
<P>Most toxicity studies concern Passiflora incarnata. The plant extract contains flavonoids and alkaloids (harman or passiflorin) (<LINK REF="REF-Olin-1989" TYPE="REFERENCE">Olin 1989</LINK>). The herbal extract may be found in tablet forms (500 mg), dried herb for oral use or by infusion, liquid extract or tincture (<LINK REF="REF-Fisher-2000" TYPE="REFERENCE">Fisher 2000</LINK>; <LINK REF="REF-Newall-1996" TYPE="REFERENCE">Newall 1996</LINK>). It has been used for many years in America, and has not been associated with acute or chronic toxicity. However, the pharmacological profile of the extracts suggests that large doses may result in central nervous system depression and bradycardia, prolonged QTc and ventricular tachycardia (<LINK REF="REF-Fisher-2000" TYPE="REFERENCE">Fisher 2000</LINK>). Although it has been used for a long time in treating anxiety disorders, its efficacy and tolerability are not yet established. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To investigate the effectiveness and safety of passiflora for treating any anxiety disorders. </P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Relevant randomised and quasi-randomised controlled trials. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with any primary diagnosis of anxiety disorders or anxiety neurosis or chronic anxiety status, or any other disease in which anxiety was a core symptom (panic disorder, obsessive compulsive disorder, social phobia, agoraphobia, other types of phobia, postraumatic stress disorder), irrespective of gender, and ethnic background, aged 16 and over. </P>
<P>Studies in which anxiety was a minor symptom of a different disorder (for example depression or any other psychiatric diagnoses) were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Passiflora extract of any dose, regime, or method of administration. Trials where passiflora was used in association with another drug were not included. </P>
<P>Comparison: placebo, other drugs, psychotherapy or no intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>
<B>
<BR/>Primary outcome</B>
<BR/>Effectiveness, measured using clinical outcome measures such as Hamilton Anxiety Scale (HAM-A) (<LINK REF="REF-Hamilton-1959" TYPE="REFERENCE">Hamilton 1959</LINK>) and other scales for anxiety symptoms:<BR/>1) improvement in anxiety (continuous outcome)<BR/>2) absence of treatment response (dichotomous outcome)</P>
<P>
<B>Secondary outcome measures</B>
<BR/>1) Acceptability of treatment :<BR/>- number of participants reporting side effects<BR/>- number of participants dropping out due to side effects.<BR/>2) Side effects<BR/>3) Dropout rates<BR/>4) Suicide attempts<BR/>5) Use/misuse of substances<BR/>6) Use of health services<BR/>7) Death <BR/>8) Quality of life</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>
<B>
<BR/>Electronic databases</B>
<BR/>The Cochrane Collaboration Depression, Anxiety and Neurosis Cochrane Controlled Trials Register (CCDANCTR-Studies), Lilacs (2005) and Medline (2005) were searched using standard phrases for 'controlled trials' and for 'anxiety disorders' associated to 'passiflora OR passionflower OR passion flower'. There was no restriction related to language or date of publication of the studies.</P>
<P>
<B>Reference lists</B>
<BR/>The references of all identified studies were inspected for additional studies. </P>
<P>
<B>Personal communication</B>
<BR/>The first author of each included study was contacted for information regarding unpublished trials and additional data when necessary. The manufacturers of passiflora products and experts in the field were also contacted for information regarding unpublished trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>
<BR/>Selection of trials</B>
<BR/>Two review authors (LSM and BGOS) independently selected the trials found through the search strategy, extracted the data, assessed trial quality and analysed the results. Where any disagreements occurred, the third review author (ANA) was consulted, and if consensus was not yet reached, data were not included in the review until the author of the trial provided further clarification.</P>
<P>
<B>Data extraction</B>
<BR/>Review authors screened the abstracts of all publications obtained by the search strategy, and considered eligible in fulfilling the inclusion criteria. Data concerning participant characteristics, intervention details and outcome measures from the included studies was extracted independently using a standard extraction form with the following items:<BR/>1) General information: published or not, title, authors, contact address, country, resource, publication idiom, publication year, duplication of publishing, sponsor.<BR/>2) Characteristics of the study: design, length, whether randomised and method, allocation procedure, blinding (patients, administrator care and outcome appraiser), allocation check.<BR/>3) Intervention: placebo inclusion, intervention and controls (dose, route of administration and duration).<BR/>4) Patients: inclusion and exclusion criteria, total number of randomised and analysed subjects, sex, age, basic characteristics, diagnostic criteria, length of disease and similarity of groups on the basic characteristics (including any co-morbidity), assessment on complications, sub-groups.<BR/>5) Outcomes: those specified in the section 'Types of outcomes', any other outcome assessed, other events, extension of attendance, and quality of related outcomes.<BR/>6) Results: outcomes and evaluation time (including the evaluative measure), where necessary converted to the measurement of the effects specified below; intention to treat analysis.</P>
<P>
<B>Quality assessment</B>
<BR/>Methodological quality of the trials included in this review was assessed using the criteria described in the Cochrane Handbook (<LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>). The Cochrane Handbook criteria are based on the evidence of a strong relationship between allocation concealment and potential for bias in the results (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). The categories for these criteria are as follows: <BR/>A - Low risk of bias (adequate allocation concealment) <BR/>B - Moderate risk of bias (unclear allocation concealment) <BR/>C - High risk of bias (inadequate allocation concealment)</P>
<P>For the purpose of the analysis in this review, trials were included if they met the criteria A or B. Additionally, a cut-off of two points in the Jadad scale was used to check the assessment made by the Cochrane Handbook criteria (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). However, the Jadad scale was not used to exclude trials in this review.</P>
<P>
<B>Measures of treatment effect</B>
</P>
<P>
<B>Dichotomous outcomes</B>
<BR/>Dichotomous outcomes were analysed by calculating relative risks (RR) for each trial with the uncertainty in each result being expressed using 95% confidence intervals (CI) and by combining individual trials in a meta-analysis. The estimates of RR were based on the random effects model, as it took into account any between study differences (even if there was no statistically significant heterogeneity) and gave the same result as the fixed effects model when there was no between study variance. When overall results were significant, it was planned to calculate the number needed to treat (NNT) or number needed to harm (NNH) to produce one outcome.</P>
<P>
<B>Continuous outcomes<BR/>
</B>Where data become available in future updates, continuous outcomes will be analysed according to their difference in mean treatment effects and its standard deviation. When multiple outcome measures are described in a single study, for the purposes of pooling results, a single 'best available' outcome measure will be chosen for each study, according to the authors' specification as the principle outcome or what is reported first. Continuous outcomes of individual studies will be combined by calculating the standardised mean difference.</P>
<P>
<B>Dealing with missing data<BR/>
</B>Information on missing data was clarified where possible through contact with the authors.</P>
<P>
<B>Assessment of heterogeneity</B>
<BR/>Heterogeneity in the results of the trials was assessed both by inspection of graphical presentations and by calculating a chi-square test of heterogeneity. Heterogeneity was assumed to be present when the significance level was lower than 0.10 (p &lt; 0.10). </P>
<P>
<B>Subgroup analysis and investigation of heterogeneity</B>
<BR/>Where additional trials with data for meta-analysis are included in future updates and significant heterogeneity is indicated to be present, an attempt will be made to explain the differences based on the clinical characteristics of the included studies. Data from these trials will be included in the meta-analysis. Potential sources of heterogeneity may include differences in sample characteristics, diagnostic criteria and differences in medication dosage. </P>
<P>
<B>Assessment of reporting biases</B>
<BR/>A funnel plot was produced to look for the possibility of publication bias. </P>
<P>
<B>Sensitivity analysis</B>
<BR/>Where further studies are included in future updates of the review, sensitivity analyses will be performed based on the exclusion of quasi-randomised studies. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>
<B>
<BR/>Results of the search</B>
<BR/>The electronic search identified two relevant references in MEDLINE (1966-2005), and three in CCCDANCTR-Studies. No references for relevant studies were found in LILACS. From the five references, three possible relevant papers were selected for further evaluation, because they evaluated the use of passiflora for anxiety. Two trials (<LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK>; <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK>) were included, and one was excluded (<LINK REF="STD-Bourin-1997" TYPE="STUDY">Bourin 1997</LINK>).</P>
<P>Manufacturers of passiflora (Marjan, Brasmedica, Infabra, Millex Roux, Biolab Sanus, Hertz, DM Ind Farmaceutica) were contacted to ask for information on unpublished trials, but no further trials were found.</P>
<P>
<B>Included studies</B>
<BR/>
<LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK>, a multicentre double blind RCT conducted in Japan, compared mexazolam with passiflora over four weeks. <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK>, a double blind RCT conducted in Iran, compared oxazolam with passiflora, also over a four-week period.</P>
<P>
<B>
<I>Participants: </I>
</B>
<BR/>In <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK>, 36 subjects with generalised anxiety disorder (DSM-IV), were included, and in <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK>, 162 subjects with neurosis/anxiety (no specific diagnostic criteria) were included. The majority of participants in the two trials were female (59%).</P>
<P>
<B>
<I>Interventions: </I>
</B>
<BR/>Passiflora was prescribed in distinct conditions in the two included studies: 45 drops/day in <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> (+ placebo tablet) and a tablet of 90 mg/day in <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK>. The distinct formulations of doses used in each study make it difficult to combine data in comparisons of passiflora against control groups.</P>
<P>
<B>
<I>Control groups:</I>
</B> <BR/>The control groups used were oxazolam 30 mg/day (+ placebo drops) in <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> and mexazolam 1.5 mg/day in <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK>.</P>
<P>
<B>Excluded studies</B>
<BR/>
<LINK REF="STD-Bourin-1997" TYPE="STUDY">Bourin 1997</LINK> compared a combination of six plant extracts with placebo, with no group receiving passiflora only.</P>
<P>
<B>Studies awaiting assessment</B>
<BR/>There are no studies awaiting assessment.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>
<B>Allocation</B>
<BR/>
<LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK> reported that randomisation was carried out by a 'central committee of randomisation', a method considered as A according to the Cochrane Handbook classification of allocation concealment. <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> did not explain how randomisation was done, and was classified as B.</P>
<P>
<B>Blinding</B>
<BR/>Both trials employed a double blind design. <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> used a double-dummy technique, since passiflora was used as drops and oxazolam as tablets.</P>
<P>
<B>Dropout rates</B>
<BR/>The trial by <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK> reported 16 dropouts in the passiflora group (completers=63) and 12 in the mexazolam group (completers=71). The trial by <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> had two dropouts in each group.</P>
<P>
<B>Jadad scores</B>
<BR/>The total Jadad score for the study conducted by <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK> was 5, and the total Jadad score for the study by <LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> was 3.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Two randomised double blind controlled trials included a total of 198 patients assigned to treatment.</P>
<P>
<B>01 PASSIFLORA vs BENZODIAZEPINES</B>
</P>
<P>
<B>Primary outcome</B>
</P>
<P>
<B>
<I>Effectiveness</I>
</B>
<B>
<BR/>
</B>In the trial by <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK>, 37% of the passiflora group and 44% of the mexazolam group showed a moderate to marked improvement (RR 1.13, 95%CI 0.85 to 1.49). </P>
<P>
<LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> presented some outcome data that could not be re-analysed in this review, showing a more rapid onset of action with oxazolam as compared with passiflora, but no difference detected at the end of the trial. The reduction in HAM-A scores was similar for both arms.</P>
<P>
<B>Secondary outcomes</B>
</P>
<P>
<B>
<I>Acceptability of treatment</I>
</B>
<B>
<BR/>
</B>In the trial by <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK>, 81% of the passiflora group and 79% of the mexazolam group reported no side effects (RR 0.90, 95%CI 0.46 to 1.78).</P>
<P>
<B>
<I>Side effects</I>
</B>
<BR/>For types of side effects, a meta-analysis pooling data from both studies was performed for drowsiness, dizziness and allergic reactions only. Those taking passiflora were less likely to be sedated (5%) than those receiving benzodiazepines (21%), but this finding did not reach statistical significance (RR 0.56, 95%CI 0.20 to 1.59, n=166). Allergic reactions (RR 0.94, 95% CI 0.22 to 4.07, n=166) and dizziness (RR 0.89, 95%CI 0.44 to 1.82, n=166) were equally present between the two interventions. Other adverse events described in the trial by <LINK REF="STD-Mori-1993" TYPE="STUDY">Mori 1993</LINK> did not differ significantly between passiflora and mexazolam.</P>
<P>
<B>
<I>Dropout <BR/>
</I>
</B>Combining data from both included studies, no significant difference in dropout rates was found between passiflora and benzodiazepines (RR 1.43, 95%CI 0.77 to 2.69). </P>
<P>
<B>
<I>Job performance (post-hoc outcome)</I>
</B>
<BR/>
<LINK REF="STD-Akhondzadeh-2001" TYPE="STUDY">Akhondzadeh 2001</LINK> reported that impairment of job performance was greater for the oxazolam group (61%) when compared with the passiflora group (44%), but this finding did not reach statistical significance (RR 0.67, 95%CI 0.38 to 1.17).</P>
<P>
<B>
<I>Other secondary outcomes</I>
</B>
<BR/>No data were available for other secondary outcomes, including suicide attempts, use/misuse of substances, use of health services, death and quality of life.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Passiflora is available on the market in a range of different preparations, mainly in tablet form (500mg) of the dried herb for oral use or by infusion, as liquid extract or as tincture (<LINK REF="REF-Fisher-2000" TYPE="REFERENCE">Fisher 2000</LINK>). In addition to variation in preparation, several different manufacturers produce formulations of passiflora, making it even more difficult to compare the efficacy of the distinct preparations. </P>
<P>In this review, two studies, evaluating two distinct formulations, were not able to differentiate passiflora from benzodiazepines for any of the outcome measures. This lack of statistical difference may be interpreted in two ways: firstly, the medications were equally effective or secondly, the absence of difference may explained due to type 2 error (sample sizes not large enough or insufficient number of studies for inclusion). </P>
<P>One important limitation of the present review is the lack of direct comparison between passiflora and antidepressants, which are now the most commonly used medication for anxiety disorders. One systematic review found that trazodone, imipramine or ritanserin were significantly more effective in the treatment of generalized anxiety disorder than placebo (<LINK REF="REF-Gould-1997" TYPE="REFERENCE">Gould 1997</LINK>). However, another review that compared antidepressants to benzodiazepines found no significant differences between the two classes (<LINK REF="REF-Rickels-1993" TYPE="REFERENCE">Rickels 1993</LINK>), suggesting a lack of clarity on this topic. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The number of randomised controlled trials examining the effectiveness of passiflora for anxiety disorders are too few to permit clear conclusions to be drawn. Evidence from two small studies show a similar pattern of response for passiflora and benzodiazepines under evaluation in short-term treatment of anxiety disorders. There are no comparisons of passiflora with the most commonly prescribed medications for these disorders, antidepressants, which limits the ability to draw any practical conclusions for clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>RCTs with larger samples, comparing passiflora to other interventions used in anxiety disorders, such as antidepressants, are needed. Furthermore it is important to conduct a proper comparison of passiflora to placebo to establish the primary efficacy and safety of this intervention.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The staff of the Brazilian Cochrane Centre for their interest in solving daily queries, and facilitating access to Cochrane databases.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>LSM - protocol writing, searching, trial selection, data extraction, completion of report</P>
<P>ANA - protocol writing, expertise advice, completion of report</P>
<P>BGOS - protocol writing, searching, trial selection, data extraction, completion of report</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Akhondzadeh-2001" NAME="Akhondzadeh 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M</AU>
<TI>Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam</TI>
<SO>Journal of Clinical Pharmacy and Therapeutics</SO>
<YR>2001</YR>
<VL>26</VL>
<PG>363-367</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-1993" NAME="Mori 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mori A, Hasegawa K, Murasaki M, Yamauchi T, et al</AU>
<TI>Clinical Evaluation of Passiflamin (passiflora extract) on neurosis - multicenter double blind study in comparison with mexazolam</TI>
<SO>Clinical Evaluation</SO>
<YR>1993</YR>
<VL>21</VL>
<PG>383-440</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourin-1997" NAME="Bourin 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bourin M, Bougerol T, Guitton B, Broutin E</AU>
<TI>A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo</TI>
<SO>Fundamental &amp; Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>2</NO>
<PG>127-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Almeida_x002d_Filho-1997" NAME="Almeida-Filho 1997" TYPE="JOURNAL_ARTICLE">
<AU>Almeida-Filho N, Mari JJ, Coutinho E, Franca JF, Fernades J, Andreoli SB et al</AU>
<TI>Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>524-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bijl-1998" NAME="Bijl 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bijl RV, Ravelli A, van Zessen G</AU>
<TI>Prevalence of psychiatric disorder in the general population: results of the Netherlans Mental Health Survey and Incidence Study (NEMESIS)</TI>
<SO>Social Psychiatry &amp; Psychiatric Epidemiology</SO>
<YR>1998</YR>
<VL>33</VL>
<NO>12</NO>
<PG>587-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borkovec-1987" NAME="Borkovec 1987" TYPE="JOURNAL_ARTICLE">
<AU>Borkovec TD, Mathews AM, Chambers A, Ebrahimi S, Lytle R, Nelson R et al</AU>
<TI>The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety disorder</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>1987</YR>
<VL>55</VL>
<NO>6</NO>
<PG>883-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borkovec-1993" NAME="Borkovec 1993" TYPE="JOURNAL_ARTICLE">
<AU>Borkovec TD, Costello E</AU>
<TI>Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder</TI>
<SO>Journal of Consulting &amp; Clinical Psychology</SO>
<YR>1993</YR>
<VL>61</VL>
<NO>4</NO>
<PG>611-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="BOOK">
<AU>Clarke M, Oxman AD</AU>
<SO>Cochrane Collaboration Handbook</SO>
<YR>2000</YR>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fisher-2000" NAME="Fisher 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fisher AA, Purcell P, Le Couteur DG</AU>
<TI>Toxicity of Passiflora incarnata</TI>
<SO>Clinical Toxicology</SO>
<YR>2000</YR>
<VL>38</VL>
<NO>1</NO>
<PG>63-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gould-1997" NAME="Gould 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gould RA, Otto MW. Pollack MH, Yap L</AU>
<TI>Cognitive behavioural and pharmacological treatment of generalized anxiety disorders: a preliminary meta-analysis</TI>
<SO>Behaviour Therapy</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>2</NO>
<PG>285-305</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1959" NAME="Hamilton 1959" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>The assessment of anxiety states by rating</TI>
<SO>British Journal of Medical Psychology</SO>
<YR>1959</YR>
<VL>32</VL>
<PG>50-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunot--2006" NAME="Hunot  2006" TYPE="COCHRANE_REVIEW">
<AU>Hunot V, Churchill R, Silva de Lima M, Teixeira V</AU>
<TI>Psychological therapies for generalised anxiety disorder [Psychotherapy for generalized anxiety disorder]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<PB>Wiley</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomised clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kessler-1994" NAME="Kessler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S et al</AU>
<TI>Lifetime and 12 month prevalence of DSM III R psychiatric disorders in the United States</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<NO>1</NO>
<PG>8-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendlowicz-2000" NAME="Mendlowicz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mendlowicz MV, Stein MB</AU>
<TI>Quality of life in individuals with anxiety disorders</TI>
<SO>American Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>157</VL>
<NO>5</NO>
<PG>669-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newall-1996" NAME="Newall 1996" TYPE="BOOK">
<AU>Newall</AU>
<SO>Herbal medicines: a guide for health care professionals</SO>
<YR>1996</YR>
<PB>The Pharmaceutical Press of Great Britain</PB>
<CY>London, England</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olin-1989" NAME="Olin 1989" TYPE="BOOK_SECTION">
<AU>Olin B</AU>
<TI>Passion Flower monograph</TI>
<SO>The Lawrence review of natural products. Facts and comparisons</SO>
<YR>1989</YR>
<PB>Wolters Kluwer Company</PB>
<CY>St Louis, MO</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pittler-2002" NAME="Pittler 2002" TYPE="COCHRANE_REVIEW">
<AU>Pitter MH, Ernst E</AU>
<TI>Kava extract for treating anxiety</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Priest-1988" NAME="Priest 1988" TYPE="JOURNAL_ARTICLE">
<AU>Priest RG, Montgomery SA</AU>
<TI>Benzodiazepines and dependence: A college statement</TI>
<SO>Bulletin of the Royal College of Psychiatrists</SO>
<YR>1988</YR>
<VL>12</VL>
<PG>107-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rickels-1993" NAME="Rickels 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rickels K, Downing R, Schweizer E, et al</AU>
<TI>Antidepressants for the treatment of generalized anxiety disorder: aplacebo controlled comparison of imipramine, trazodone and diazepam</TI>
<SO>Arch Gen Psychiatry</SO>
<YR>1993</YR>
<VL>50</VL>
<PG>884-895</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmmers I, Haves RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimension of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1978" NAME="Taylor 1978" TYPE="BOOK">
<AU>Taylor CB</AU>
<SO>Relaxation training and related techniques In: Behavioral modifications: principles and clinical applications</SO>
<YR>1978</YR>
<ED>Agras WS</ED>
<PB>Little Brown</PB>
<CY>Boston, MA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taylor-1988" NAME="Taylor 1988" TYPE="BOOK">
<AU>Taylor CB, Arnow B</AU>
<SO>The nature and the treatment of anxiety disorders</SO>
<YR>1988</YR>
<PB>Free Press</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walley-1994" NAME="Walley 1994" TYPE="JOURNAL_ARTICLE">
<AU>Walley EJ, Beebe DK, Clark JL</AU>
<TI>Management of common anxiety disorders</TI>
<SO>American Family Physician</SO>
<YR>1994</YR>
<VL>50</VL>
<NO>8</NO>
<PG>1745-53</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Akhondzadeh-2001">
<CHAR_METHODS>
<P>RCT <BR/>double blind<BR/>4 weeks<BR/>non-ITT<BR/>Iran</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>GAD (DSM-IV)<BR/>N=36<BR/>20 female<BR/>age range=19-47<BR/>outpatient</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Passiflora 45 drops/day + placebo tablet n=18<BR/>2. Oxazolam tablet 30 mg + placebo drops n=18</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>HAM-A<BR/>Side effects Impairment of job performance<BR/>Dropout</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data from HAM-A presented on graphic</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mori-1993">
<CHAR_METHODS>
<P>RCT (randomisation by a central commitee) <BR/>double blind <BR/>4 weeks<BR/>multicentre, Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Neurosis/ Anxiety<BR/>N=162<BR/>79 female<BR/>age range=15-70</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Passiflora 90 mg n=63<BR/>2. Mexazolam 1.5 mg n=71</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>FGIR<BR/>OSR<BR/>Dropout</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BZD=Benzodiazepines<BR/>FGIR=Final Global Improvement Rate<BR/>GAD=Generalised Anxiety Disorder<BR/>GUR=Global utility Rate<BR/>HAM-A=Hamilton Anxiety<BR/>OSR=Overall Safety Rate</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bourin-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>combination of plant extract<BR/>multicenter<BR/>double blind placebo controlled<BR/>adjustment disorder with anxious mood<BR/>28 days<BR/>HAM-A</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Akhondzadeh-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mori-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Passiflora vs Benzodiazepines</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.487385833894941" CI_START="0.8539097210225854" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.1724236408797462" LOG_CI_START="-0.06858804234875908" LOG_EFFECT_SIZE="0.05191779926549358" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.39843719714195247" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.8444156345771071">
<NAME>Lack of moderate/marked improvement (FGIR)</NAME>
<GROUP_LABEL_1>Passiflora</GROUP_LABEL_1>
<GROUP_LABEL_2>BZD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours passiflora</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BZD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.487385833894941" CI_START="0.8539097210225854" DF="0.0" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.1724236408797462" LOG_CI_START="-0.06858804234875908" LOG_EFFECT_SIZE="0.05191779926549358" NO="1" P_CHI2="1.0" P_Z="0.39843719714195247" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.8444156345771071">
<NAME>Mexazolam</NAME>
<DICH_DATA CI_END="1.487385833894941" CI_START="0.8539097210225854" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" LOG_CI_END="0.1724236408797462" LOG_CI_START="-0.06858804234875908" LOG_EFFECT_SIZE="0.05191779926549358" ORDER="237" O_E="0.0" SE="0.14157145575549687" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="0.020042477084730607" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7779716557326186" CI_START="0.4571837013051429" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9015873015873016" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.24992483320504" LOG_CI_START="-0.3399092606901657" LOG_EFFECT_SIZE="-0.04499221374256283" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.7649324875643708" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.29900990611715467">
<NAME>Number of subjects reporting side-effects</NAME>
<GROUP_LABEL_1>Passiflora</GROUP_LABEL_1>
<GROUP_LABEL_2>BZD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours passiflora</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BZD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7779716557326184" CI_START="0.45718370130514296" EFFECT_SIZE="0.9015873015873016" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.24992483320503994" LOG_CI_START="-0.33990926069016564" LOG_EFFECT_SIZE="-0.04499221374256283" ORDER="238" O_E="0.0" SE="0.3464714664798973" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="0.1200424770847306" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.357773526449716" CI_END="1.1488615915467497" CI_START="0.5620715647740662" CI_STUDY="95" CI_TOTAL="95" DF="28.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8035810055430042" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.060267710456596034" LOG_CI_START="-0.2502083851288454" LOG_EFFECT_SIZE="-0.09497033733612469" METHOD="MH" NO="3" P_CHI2="0.9411835425880033" P_Q="0.0" P_Z="0.23050787592167898" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1499" TOTAL_2="1667" WEIGHT="2600.0" Z="1.1990516720937032">
<NAME>Side-effects</NAME>
<GROUP_LABEL_1>Passiflora</GROUP_LABEL_1>
<GROUP_LABEL_2>BZD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours passiflora</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BZD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>agression</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="239" O_E="0.0" SE="0.0" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8025654053702969" CI_END="4.065272728040197" CI_START="0.21726786732555348" DF="1.0" EFFECT_SIZE="0.9398154796118375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.6090896865376583" LOG_CI_START="-0.6630044985993354" LOG_EFFECT_SIZE="-0.026957406030838616" NO="2" P_CHI2="0.37032751378252793" P_Z="0.9337969888227071" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="87" WEIGHT="100.0" Z="0.08306860538219753">
<NAME>allergic reaction</NAME>
<DICH_DATA CI_END="3.469777208882954" CI_START="0.12809019648484204" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5403015900476403" LOG_CI_START="-0.8924841081590029" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="240" O_E="0.0" SE="0.8416254115301731" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.7083333333333333" WEIGHT="78.82719252724442"/>
<DICH_DATA CI_END="81.38916302522009" CI_START="0.13995260028009365" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="241" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="21.17280747275558"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.354528276537512" CI_START="0.10617838082099462" DF="0.0" EFFECT_SIZE="0.5000000000000001" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="0.371903910438316" LOG_CI_START="-0.9739639017662782" LOG_EFFECT_SIZE="-0.3010299956639811" NO="3" P_CHI2="1.0" P_Z="0.3806118373804923" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.876769537717365">
<NAME>ataxia</NAME>
<DICH_DATA CI_END="2.3545282765375117" CI_START="0.10617838082099462" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.3719039104383159" LOG_CI_START="-0.9739639017662782" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="242" O_E="0.0" SE="0.7905694150420949" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.625" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.320873727002171" CI_START="0.30112557182435323" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.5212523622865003" LOG_CI_START="-0.5212523622865004" LOG_EFFECT_SIZE="0.0" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>confusion</NAME>
<DICH_DATA CI_END="3.320873727002171" CI_START="0.30112557182435323" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5212523622865003" LOG_CI_START="-0.5212523622865004" LOG_EFFECT_SIZE="0.0" ORDER="243" O_E="0.0" SE="0.6123724356957945" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>disinhibition</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="244" O_E="0.0" SE="0.0" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03152895808976721" CI_END="1.8201060318440094" CI_START="0.4352931461761209" DF="1.0" EFFECT_SIZE="0.890100938644328" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="0.2600966889210198" LOG_CI_START="-0.3612181708883726" LOG_EFFECT_SIZE="-0.050560740983676376" NO="6" P_CHI2="0.8590654762047828" P_Z="0.7497325883050134" STUDIES="2" TAU2="0.0" TOTAL_1="79" TOTAL_2="87" WEIGHT="99.99999999999999" Z="0.3189919886675979">
<NAME>dizziness</NAME>
<DICH_DATA CI_END="1.8354053603053626" CI_START="0.4171421837150025" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.26373199572815714" LOG_CI_START="-0.3797158896835307" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="245" O_E="0.0" SE="0.3779644730092272" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.14285714285714285" WEIGHT="93.23881070786159"/>
<DICH_DATA CI_END="17.646109821416747" CI_START="0.07197581990182829" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2466489777518075" LOG_CI_START="-1.1428133792208202" LOG_EFFECT_SIZE="0.05191779926549358" ORDER="246" O_E="0.0" SE="1.4035820165151485" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="1.9700424770847307" WEIGHT="6.761189292138397"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.0087797381357086" CI_END="1.5919023481764931" CI_START="0.19913080065038777" DF="1.0" EFFECT_SIZE="0.5630246789880684" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="18" I2="50.21853411723121" ID="CMP-001.03.07" LOG_CI_END="0.20191642335841245" LOG_CI_START="-0.7008615600733599" LOG_EFFECT_SIZE="-0.24947256835747364" NO="7" P_CHI2="0.1563914372751155" P_Z="0.2787071975795916" STUDIES="2" TAU2="0.29194524988145143" TOTAL_1="79" TOTAL_2="87" WEIGHT="100.0" Z="1.0832281205012533">
<NAME>drowsiness</NAME>
<DICH_DATA CI_END="1.9892865331828329" CI_START="0.3693253160345481" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.2986973426104674" LOG_CI_START="-0.4325909218716939" LOG_EFFECT_SIZE="-0.06694678963061322" ORDER="247" O_E="0.0" SE="0.4295623464921123" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.18452380952380953" WEIGHT="68.12007040244389"/>
<DICH_DATA CI_END="1.0522859547786656" CI_START="0.08977573385958913" EFFECT_SIZE="0.30735930735930733" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="0.022133773759761985" LOG_CI_START="-1.0468410361059002" LOG_EFFECT_SIZE="-0.5123536311730691" ORDER="248" O_E="0.0" SE="0.6279210948257391" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="0.3942849013271548" WEIGHT="31.879929597556107"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.8634844753344426" CI_START="0.010353348190052555" DF="0.0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.03.08" LOG_CI_END="0.5869791714561268" LOG_CI_START="-1.9849191801281645" LOG_EFFECT_SIZE="-0.6989700043360187" NO="8" P_CHI2="1.0" P_Z="0.2867281151029345" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.0653267334057028">
<NAME>dyspnea</NAME>
<DICH_DATA CI_END="3.8634844753344426" CI_START="0.010353348190052555" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5869791714561268" LOG_CI_START="-1.9849191801281645" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="249" O_E="0.0" SE="1.5107458228227775" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="2.282352941176471" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.618637080220918" CI_START="0.014584119172649873" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.09" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.4771212547196625" NO="9" P_CHI2="1.0" P_Z="0.49138352315933886" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.6881099923337485">
<NAME>hyporeflexia</NAME>
<DICH_DATA CI_END="7.618637080220918" CI_START="0.014584119172649873" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8818772861059678" LOG_CI_START="-1.8361197955452926" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="250" O_E="0.0" SE="1.5965649400644928" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="2.5490196078431375" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5600096199864333" CI_START="0.007971908818613843" DF="0.0" EFFECT_SIZE="0.14285714285714288" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-001.03.10" LOG_CI_END="0.40824159730371445" LOG_CI_START="-2.098437677332228" LOG_EFFECT_SIZE="-0.8450980400142567" NO="10" P_CHI2="1.0" P_Z="0.18631519149863693" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.3215585564482673">
<NAME>respiratory depression</NAME>
<DICH_DATA CI_END="2.560009619986433" CI_START="0.007971908818613843" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.40824159730371434" LOG_CI_START="-2.098437677332228" LOG_EFFECT_SIZE="-0.8450980400142569" ORDER="251" O_E="0.0" SE="1.47243581418368" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="2.1680672268907566" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="11" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>slurred speech</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="252" O_E="0.0" SE="0.0" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.043240336135563" CI_START="0.015550288920010412" DF="0.0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.12" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" NO="12" P_CHI2="1.0" P_Z="0.5458539770267063" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.6039844601961157">
<NAME>abdominal fullness</NAME>
<DICH_DATA CI_END="9.043240336135563" CI_START="0.015550288920010412" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="253" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.38916302522009" CI_START="0.13995260028009365" DF="0.0" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.13" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" NO="13" P_CHI2="1.0" P_Z="0.45383093377668626" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.7490435986603111">
<NAME>abnormality of salivation</NAME>
<DICH_DATA CI_END="81.38916302522009" CI_START="0.13995260028009365" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="254" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="114.99131176893727" CI_START="0.27515665760538893" DF="0.0" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.03.14" LOG_CI_END="2.0606650282375294" LOG_CI_START="-0.5604199746707292" LOG_EFFECT_SIZE="0.7501225267834001" NO="14" P_CHI2="1.0" P_Z="0.2619323963220026" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="1.1218355260179296">
<NAME>anorexia</NAME>
<DICH_DATA CI_END="114.99131176893727" CI_START="0.27515665760538893" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0606650282375294" LOG_CI_START="-0.5604199746707292" LOG_EFFECT_SIZE="0.7501225267834001" ORDER="255" O_E="0.0" SE="1.539638305288327" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.370486111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.38916302522009" CI_START="0.13995260028009365" DF="0.0" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.15" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" NO="15" P_CHI2="1.0" P_Z="0.45383093377668626" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.7490435986603111">
<NAME>blurred vision</NAME>
<DICH_DATA CI_END="81.38916302522009" CI_START="0.13995260028009365" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="256" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.38916302522009" CI_START="0.13995260028009365" DF="0.0" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.16" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" NO="16" P_CHI2="1.0" P_Z="0.45383093377668626" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.7490435986603111">
<NAME>chest discomfort</NAME>
<DICH_DATA CI_END="81.38916302522009" CI_START="0.13995260028009365" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="257" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.043240336135563" CI_START="0.015550288920010412" DF="0.0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.17" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" NO="17" P_CHI2="1.0" P_Z="0.5458539770267063" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.6039844601961157">
<NAME>constipation</NAME>
<DICH_DATA CI_END="9.043240336135563" CI_START="0.015550288920010412" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="258" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="114.99131176893727" CI_START="0.27515665760538893" DF="0.0" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.03.18" LOG_CI_END="2.0606650282375294" LOG_CI_START="-0.5604199746707292" LOG_EFFECT_SIZE="0.7501225267834001" NO="18" P_CHI2="1.0" P_Z="0.2619323963220026" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="1.1218355260179296">
<NAME>diarrhea</NAME>
<DICH_DATA CI_END="114.99131176893727" CI_START="0.27515665760538893" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0606650282375294" LOG_CI_START="-0.5604199746707292" LOG_EFFECT_SIZE="0.7501225267834001" ORDER="259" O_E="0.0" SE="1.539638305288327" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.370486111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.043240336135563" CI_START="0.015550288920010412" DF="0.0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.19" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" NO="19" P_CHI2="1.0" P_Z="0.5458539770267063" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.6039844601961157">
<NAME>discouragement</NAME>
<DICH_DATA CI_END="9.043240336135563" CI_START="0.015550288920010412" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="260" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="114.99131176893727" CI_START="0.27515665760538893" DF="0.0" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.03.20" LOG_CI_END="2.0606650282375294" LOG_CI_START="-0.5604199746707292" LOG_EFFECT_SIZE="0.7501225267834001" NO="20" P_CHI2="1.0" P_Z="0.2619323963220026" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="1.1218355260179296">
<NAME>fatigue</NAME>
<DICH_DATA CI_END="114.99131176893727" CI_START="0.27515665760538893" EFFECT_SIZE="5.625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0606650282375294" LOG_CI_START="-0.5604199746707292" LOG_EFFECT_SIZE="0.7501225267834001" ORDER="261" O_E="0.0" SE="1.539638305288327" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.370486111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.043240336135563" CI_START="0.015550288920010412" DF="0.0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.21" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" NO="21" P_CHI2="1.0" P_Z="0.5458539770267063" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.6039844601961157">
<NAME>headache</NAME>
<DICH_DATA CI_END="9.043240336135563" CI_START="0.015550288920010412" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="262" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.38916302522009" CI_START="0.13995260028009365" DF="0.0" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.22" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" NO="22" P_CHI2="1.0" P_Z="0.45383093377668626" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.7490435986603111">
<NAME>heart pressure</NAME>
<DICH_DATA CI_END="81.38916302522009" CI_START="0.13995260028009365" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="263" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.043240336135563" CI_START="0.015550288920010412" DF="0.0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.23" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" NO="23" P_CHI2="1.0" P_Z="0.5458539770267063" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.6039844601961157">
<NAME>inarticulateness</NAME>
<DICH_DATA CI_END="9.043240336135563" CI_START="0.015550288920010412" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="264" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.599652470757491" CI_START="0.011006266304215554" DF="0.0" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-001.03.24" LOG_CI_END="0.6627250195654918" LOG_CI_START="-1.958359983342767" LOG_EFFECT_SIZE="-0.6478174818886375" NO="24" P_CHI2="1.0" P_Z="0.33262772765253457" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.9688346098263487">
<NAME>light head feeling</NAME>
<DICH_DATA CI_END="4.599652470757491" CI_START="0.011006266304215554" EFFECT_SIZE="0.225" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6627250195654918" LOG_CI_START="-1.958359983342767" LOG_EFFECT_SIZE="-0.6478174818886375" ORDER="265" O_E="0.0" SE="1.539638305288327" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.370486111111111" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.043240336135563" CI_START="0.015550288920010412" DF="0.0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.25" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" NO="25" P_CHI2="1.0" P_Z="0.5458539770267063" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.6039844601961157">
<NAME>nausea</NAME>
<DICH_DATA CI_END="9.043240336135563" CI_START="0.015550288920010412" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="266" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.646109821416747" CI_START="0.07197581990182829" DF="0.0" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.03.26" LOG_CI_END="1.2466489777518075" LOG_CI_START="-1.1428133792208202" LOG_EFFECT_SIZE="0.05191779926549358" NO="26" P_CHI2="1.0" P_Z="0.9321250678026077" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.0851714750140449">
<NAME>numbness</NAME>
<DICH_DATA CI_END="17.646109821416747" CI_START="0.07197581990182829" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2466489777518075" LOG_CI_START="-1.1428133792208202" LOG_EFFECT_SIZE="0.05191779926549358" ORDER="267" O_E="0.0" SE="1.4035820165151485" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="1.9700424770847307" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="17.646109821416747" CI_START="0.07197581990182829" DF="0.0" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.03.27" LOG_CI_END="1.2466489777518075" LOG_CI_START="-1.1428133792208202" LOG_EFFECT_SIZE="0.05191779926549358" NO="27" P_CHI2="1.0" P_Z="0.9321250678026077" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.0851714750140449">
<NAME>stomach ache</NAME>
<DICH_DATA CI_END="17.646109821416747" CI_START="0.07197581990182829" EFFECT_SIZE="1.126984126984127" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2466489777518075" LOG_CI_START="-1.1428133792208202" LOG_EFFECT_SIZE="0.05191779926549358" ORDER="268" O_E="0.0" SE="1.4035820165151485" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="1.9700424770847307" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.043240336135563" CI_START="0.015550288920010412" DF="0.0" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.03.28" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" NO="28" P_CHI2="1.0" P_Z="0.5458539770267063" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.6039844601961157">
<NAME>thirst</NAME>
<DICH_DATA CI_END="9.043240336135563" CI_START="0.015550288920010412" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9563240729478506" LOG_CI_START="-1.8082615374924127" LOG_EFFECT_SIZE="-0.42596873227228116" ORDER="269" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.38916302522009" CI_START="0.13995260028009365" DF="0.0" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.03.29" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" NO="29" P_CHI2="1.0" P_Z="0.45383093377668626" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="100.0" Z="0.7490435986603111">
<NAME>weakness</NAME>
<DICH_DATA CI_END="81.38916302522009" CI_START="0.13995260028009365" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9105665823871756" LOG_CI_START="-0.8540190280530879" LOG_EFFECT_SIZE="0.5282737771670437" ORDER="270" O_E="0.0" SE="1.6239312724920898" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="2.6371527777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.16526424231218867" CI_END="2.6853080210880607" CI_START="0.7654671142989277" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4337067279977596" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.42899410909938823" LOG_CI_START="-0.11607346255591663" LOG_EFFECT_SIZE="0.1564603232717358" METHOD="MH" NO="4" P_CHI2="0.6843556252109978" P_Q="0.0" P_Z="0.26050185107067225" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="89" WEIGHT="100.00000000000001" Z="1.1252058077526679">
<NAME>Dropout</NAME>
<GROUP_LABEL_1>Passiflora</GROUP_LABEL_1>
<GROUP_LABEL_2>BZD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours passiflora</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BZD</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.346298729995294" CI_START="0.15757216017480813" DF="0.0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.8025205111515716" LOG_CI_START="-0.8025205111515716" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="11.53263152039383" Z="0.0">
<NAME>Oxazepam</NAME>
<DICH_DATA CI_END="6.346298729995294" CI_START="0.15757216017480813" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8025205111515716" LOG_CI_START="-0.8025205111515716" LOG_EFFECT_SIZE="0.0" ORDER="271" O_E="0.0" SE="0.9428090415820634" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.8888888888888888" WEIGHT="11.53263152039383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.928263170198494" CI_START="0.771086263557281" DF="0.0" EFFECT_SIZE="1.5026455026455026" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.46661010525142965" LOG_CI_START="-0.1128970335038426" LOG_EFFECT_SIZE="0.17685653587379352" NO="2" P_CHI2="1.0" P_Z="0.23157919964207085" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="71" WEIGHT="88.46736847960618" Z="1.1963008479505044">
<NAME>Mexazolam</NAME>
<DICH_DATA CI_END="2.928263170198494" CI_START="0.771086263557281" EFFECT_SIZE="1.5026455026455026" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.46661010525142965" LOG_CI_START="-0.1128970335038426" LOG_EFFECT_SIZE="0.17685653587379352" ORDER="272" O_E="0.0" SE="0.34040536191144805" STUDY_ID="STD-Mori-1993" TOTAL_1="63" TOTAL_2="71" VAR="0.11587581041806393" WEIGHT="88.46736847960618"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1738955626987648" CI_START="0.3786064608870951" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.06962946099917963" LOG_CI_START="-0.4218119791105422" LOG_EFFECT_SIZE="-0.17609125905568127" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.16014848769322765" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.4045723358794968">
<NAME>Impairment of job performance</NAME>
<GROUP_LABEL_1>Passiflora</GROUP_LABEL_1>
<GROUP_LABEL_2>BZD</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours passiflora</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours BZD</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1738955626987648" CI_START="0.3786064608870951" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.06962946099917963" LOG_CI_START="-0.4218119791105422" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="273" O_E="0.0" SE="0.28867513459481287" STUDY_ID="STD-Akhondzadeh-2001" TOTAL_1="16" TOTAL_2="16" VAR="0.08333333333333331" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>